If you have been reading about preclinical models and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
== Prevalence == The National Center for Health Statistics estimates that, for 2015–2016 in the U.S., 39.8% of adults aged 20 and over were obese (including 7.6% with severe obesity) and that another 31.8% were overweight. In the NCHS update for 2018, statistics on severe obesity among U.S. adults had already climbed to 9.2% while the total obesity prevalence had reached 42.4%. This also marked the first time in American history that the obesity rates had reached or exceeded 2/5 people in every adult age group. Obesity rates have increased for all population groups in the United States over the last several decades. Between 1986 and 2000, the prevalence of severe obesity (BMI ≥ 40 kg/m2) quadrupled from one in two hundred Americans to one in fifty. Extreme obesity (BMI ≥ 50 kg/m2) in adults increased by a factor of five, from one in two thousand to one in four hundred. Previous studies often show that lower income is associated with higher risk of obesity. The CDC once again provides the statistics, concluding that, "During 2011–2014, the age-adjusted prevalence of obesity among adults was lower in the highest income group (31.2%) than the other groups (40.8% [>130% to ≤350%] and 39.0% [≤130%])." There have been similar increases seen in children and adolescents, with the prevalence of overweight in pediatric age groups nearly tripling over the same period. Approximately nine million children over six years of age are considered obese. Several recent studies have shown that the rise in obesity in the US is slowing, possibly explained by saturation of health-oriented media.
In addition to the mixture before drying, if necessary, other additives (e.g. extract, sweetener, spices, coloring matter, etc.) may be added. As a result, alcohol powder can be said to be an alcoholic beverage that is "dry". For example, a "dry martini" made from alcohol powder may be referred to as a "dry dry martini" or "dried dry martini". There are other methods for drying foods, but none are used for making alcohol powder. Typically, when considering the quality of a powdered product such as coffee, freeze drying seems to be better than spray drying, but this does not apply to alcohol powder production. In fact, "freeze-dried beer spice" was made by university students for their research. Carbon dioxide, water and alcohol have all been lost. However, due to the higher volatility of alcohol compared to water, time-consuming methods such as freeze drying should not be used. By selective diffusion, loss of alcohol is relatively small.
Diabetes burden and access to care vary widely between and within countries. Between 1990 and 2022, diabetes prevalence rose faster in low and middle income countries than in high-income countries. In 2022, more than half of adults aged 30 and over with diabetes were not taking medication for it, and treatment coverage was lowest in low and middle income countries. A pooled analysis of 1,108 population-based studies estimated that in most countries, especially low and middle income ones, treatment had not increased enough to keep pace with rising prevalence, and that the gap in treatment coverage between the countries widened from 56 percentage points in women and 43 in men in 1990 to 78 and 71 respectively in 2022. WHO reported in 2021 that essential diabetes medicines were available in only about half of facilities in low and lower middle income countries, compared to about 80% of facilities globally. The International Diabetes Federation estimated that 252 million adults aged 20–79 were unaware they had diabetes in 2024. Risk also differs between ethnic groups. South Asian people tend to develop type 2 diabetes earlier in life and often at a normal body mass index. In a study of British Pakistani and British Bangladeshi participants, those with a high genetic risk of both insulin deficiency and unfavourable fat distribution were diagnosed about 8 years earlier, at a BMI about 3 kg/m² lower, than those at low genetic risk. Disparities are also documented for Indigenous peoples.
Sources: en.wikipedia.org
Alongside many domestic obligations, more than 3,000 Canadian Armed Forces (CAF) personnel are deployed in multiple foreign military operations. The Canadian unified forces comprise the Royal Canadian Navy, Canadian Army, and Royal Canadian Air Force. The nation employs a professional, volunteer force of approximately 68,000 active personnel and 27,000 reserve personnel. Canada will spend 2% of its GDP on defence by the 2026 fiscal year, up from 1.3% and 1.4% in previous years. Peacekeeping is deeply embedded in Canadian culture and a distinguishing feature that Canadians feel sets their foreign policy apart from the United States. Canada has long been reluctant to participate in military interventions that are not sanctioned by the United Nations, such as the Vietnam War, the 2003 invasion of Iraq and the 2026 Iran war. Since the 21st century, Canadian direct participation in UN peacekeeping efforts has greatly declined. The large decrease was a result of Canada directing its participation to UN-sanctioned military operations through the North Atlantic Treaty Organization, rather than directly through the UN. The change to participation via NATO has resulted in a shift towards more militarized and deadly missions rather than traditional peacekeeping duties.
== Pharmacology == Nordazepam is a partial agonist at the GABAA receptor, which makes it less potent than other benzodiazepines, particularly in its amnesic and muscle-relaxing effects. Its elimination half-life is between 36 and 200 hours, with wide variation among individuals; factors such as age and sex are known to impact it. The variation of reported half-lives are attributed to differences in nordazepam metabolism and that of its metabolites as nordazepam is hydroxylated to active metabolites such as oxazepam, before finally being glucuronidated and excreted in the urine. This can be attributed to extremely variable hepatic and renal metabolic functions among individuals depending upon a number of factors (including age, ethnicity, disease, and current or previous use/abuse of other drugs/medicines).
== History == In 1982, Dan Duchaine formulated the first pre-workout, called Ultimate Orange, in Venice, California. Ultimate Orange was commonly used among bodybuilders. Between the late 1990s and early 2000s, consumers alleged that an active ingredient in Ultimate Orange, called Ephedra, caused high blood pressure, strokes, seizures, cardiac arrhythmia, and heart attacks. The risk of using Ephedra gave rise to creatine. Creatine is a supplement that was used by a lot of athletes in the 1992 Olympics where it gained most of its popularity from. Creatine was considered a form of pre-workout in the late 1990s until the early 2000s where it was then later used with a mixture of other supplements. Creatine was negatively received when it was first introduced to the public until the last decade where it is now one of the most used supplements. In the early 2000s, supplement companies created more potent forms of pre-workout that caused the blood flow in muscles to increase temporarily, giving lifters a better "pump." These more potent supplements are called Arginine AKG, Arginine Malate, and Citrulline. In 2005, chemist Patrick Arnold formulated a pre-workout which contained a new ingredient called DMAA (dimethylamylamine). The product Jack3d gained notoriety for its potency, but its high concentrations of DMAA were suspected of causing shortness of breath, chest pain, and an elevated risk of heart attacks. Jack3d was banned in 2012 by the FDA.
=== Books === Heseltine's book Where There's A Will was written by a team of ghostwriters directed by Keith Hampson and Julian Haviland (former political editor of ITN and The Times). Academics, businessmen and economists contributed, and he often had them thresh out ideas in front of him. "He acquires by social intercourse the knowledge that other people acquire by reading", one adviser commented. The collated drafts were then rewritten by Haviland to "give it one voice". Hugo Young called it "the most impressive [book of its kind] I've read by a modern Conservative". Heseltine's second book, The Challenge of Europe: Can Britain Win?, appeared in 1989. Heseltine was in close touch with President of the European Commission Jacques Delors, who paid a 3-hour visit to his Victoria office, diplomats Nicholas Henderson and Antony Acland and economist Christopher Johnson, who is thought to have persuaded him of the merits of European monetary union. The book won a £10,000 Adolphe Bentincke prize for advancing European unity. Heseltine was a qualified supporter of the social charter (a stronger precursor to the Social Chapter from which John Major would later opt out in the Maastricht Treaty). He was seen as devoted to Europe as a matter of what he perceived as Britain's self-interest, not on an emotional level like Edward Heath, Roy Jenkins or Kenneth Clarke.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.